Introduction
The 5th China Obesity Conference (COC2026) will be held in Beijing from 7 to 9 August 2026. As one of the most influential academic conferences in the field of obesity in China, the meeting will bring together experts in bariatric and metabolic surgery, endocrinology and metabolism, clinical nutrition, cardiovascular disease, public health, and basic research to discuss the latest advances and future trends in obesity prevention and treatment.
Ahead of the meeting, MedJ Endocrine Channel invited leading experts from the presidium of the China Obesity Federation (COF) to share the latest research priorities, innovative treatment concepts, and future directions in obesity, building momentum for COC2026. In this installment, Professor Peng Zhang of Beijing Friendship Hospital, Capital Medical University, discusses the "3.0 era" of obesity care, the evolving treatment paradigm for obesity and its related diseases, and the role of bariatric and metabolic surgery and comprehensive treatment in achieving a cure for obesity.
Q&A
Q: Could you explain what the "3.0 era" of obesity care refers to, and how it will reshape the treatment paradigm for obesity and its related diseases?
A: Today, both bariatric and metabolic surgery and the broader field of obesity treatment have entered the "3.0 era."
The period before 2000 can be regarded as the "1.0 era" of obesity treatment. In that phase, regardless of the modality used, the goal was primarily focused on weight loss.
After 2000, obesity treatment entered the "2.0 era." In addition to weight reduction, clinical practice placed greater emphasis on the improvement or even reversal of obesity-related diseases — including type 2 diabetes, hypertension, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD), obstructive sleep apnea (OSA), and polycystic ovary syndrome (PCOS) — and ultimately, through improvement of these conditions, on reducing the risk of cardiovascular and cerebrovascular events and improving cardiovascular outcomes for patients.
Today, obesity treatment has entered the "3.0 era." A defining feature of the 3.0 era is the broader range of treatment modalities available — including bariatric and metabolic surgery, and the new generation of weight-loss drugs that have continued to develop in recent years. The efficacy of these interventions in reducing weight has improved substantially, and their effects in treating obesity-related diseases have also improved markedly. As a result, obesity treatment is moving from a focus on weight loss alone and disease remission toward a new phase of obesity cure.
Obesity cure should include several goals: first, normalization of body fat; second, remission of obesity-related metabolic diseases; and on this foundation, preservation of muscle and bone mass to the extent possible, to maintain musculoskeletal health. The ultimate goal is to achieve comprehensive health— that is, physical health, mental health, and healthy social functioning — so that patients can truly return to a normal life.
About the Expert — Peng Zhang, MD
· Chief physician, PhD Supervisor
· Director, Department of Bariatric and Metabolic Surgery (designated as the "National Bariatric Team"), Beijing Friendship Hospital, Capital Medical University
· President, Bariatric and Metabolic Physicians Branch, Beijing Medical Association
· Director, Beijing Quality Control and Improvement Center for Bariatric and Metabolic Surgery
· Executive Director, Editorial Committee of the National Health Commission (NHC) Guidelines for Diagnosis and Treatment of Obesity (2024 Edition)
· Executive Chair, China Obesity Conference (COC)
· Advanced Training in Minimally Invasive and Bariatric Surgery, Duke University
· Certified physician, American Society for Metabolic and Bariatric Surgery (ASMBS)
· Speaker, Global Leadership Summit in Bariatric and Metabolic Surgery
· A senior bariatric and metabolic surgeon with more than 20 years of experience in minimally invasive treatment of obesity, diabetes, and other metabolic diseases, having performed several thousand high-quality minimally invasive bariatric procedures as primary surgeon.